CoChat
Cited by 271

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Recognition of thalidomide defects.

Open access
Smithells, R W, Newman, C G · 1992 · Journal of Medical Genetics

Abstract

Thalidomide: a brief history Thalidomide (alpha-phthalimido-glutarimide) was developed by the German firm Chemie Grunenthal as an anticonvulsant drug.Early trials showed it to be unsuitable for this pur- pose but indicated that it had sedative proper- ties.Furthermore, it had one remarkable prop- erty: overdoses simply caused prolonged sleep, not death.The drug was first marketed in Germany in 1957 under the name Contergan, and in the UK in April 1958 as Distaval.Later, compound preparations which combined tha- lidomide with other drugs were marketed for a wide variety of indications: Asmaval for asthma, Tensival for hypertension, Valgraine for migraine, and so forth.The promotion of these products laid great stress on the safety of thalidomide, based on the remarkable property described above.German paediatricians and geneticists began to see children with gross limb malfor- mations of a most unusual pattern.When two cases were shown at a paediatric meeting in Kassel by Kosenow and Pfeiffer in October 1960, few people present had ever seen similar limb defects.Wiedemann in 1961 described 13 affected infants who had been referred to him over a period of 10 months, and noted that this amounted to an epidemic.He drew attention to a number of associated malformations in these children, including congenital heart dis- ease, microphthalmos and coloboma, intestinal atresia, renal malformations, abnormal pinnae, and facial naevus.In November 1961, Lenz suggested that these deformities resulted from the mothers having taken thalidomide.By a remarkable coincidence, the same suggestion was made at much the same time by McBride in Australia.Confirmation of this suggestion came rapidly from all parts of the British Isles, Kenya, Japan, Sweden, Belgium, Switzerland, Lebanon, Israel, Peru, Canada, Brazil, the Netherlands, and the USA.The drug had been released only for clinical trials in the USA because of concerns following reports from Europe of irreversible peripheral neur- itis as a side effect of thalidomide.Consequently there were very few cases.By con- trast, it had been on sale over the counter in Germany, and there were consequently more affected children there than anywhere else.In the UK the drug was available on prescription only, but it was used very widely for, among other problems, common symptoms of early pregnancy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jmg.29.10.716

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 271

Metadata

Authors
Smithells, R. W., & Newman, C. G.
Venue
Journal of Medical Genetics
Publisher
BMJ
Published
1992-10
Volume
29
Issue
10
Pages
716-723
ISSN
  • 0022-2593 (ISSN-L)
  • 1468-6244
OpenAlex
W2163445917
Cited by
271
References
9
FWCI
1.76
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.